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Abstract
Introduction: The  aortic  valve  regurgitation  (AR)  is  a  heart  defect  consisting  of  the
retrograde flow of blood from the aorta to the left ventricle due to the improper closure of the
aortic valve leaflets. It occurs approximately in 13% of men and 8.5% of women, and the
incidence increases with age. A crucial issue in regards to a patient with asymptomatic AR,
especially  of  a  high  degree,  is  determination  of  the  time  of  qualification  for  invasive
treatment.
Aim: To draw attention to the necessity of holistic approach to a patient with asymptomatic
high-grade aortic regurgitation.  Moreover, the complications of delayed implementation of
invasive treatment were discussed.
Case report: A clinical case of a 62-year-old patient with a history of coronary artery bypass
grafting  and  with  AR  –  stage  II,  accidentally  detected  two  years  later  in  a  control
echocardiogram,  was  presented.  Despite  gradual  progress  of  regurgitation,  none  of  the
disturbing symptoms were noted, whereas cardiac parameters were systematically monitored
using  ECG,  ECHO and  CT imaging.  Beta  blockers,   ACE inhibitors,  loop diuretics  and
aspirin were used as conservative treatment.  After 10-year transthoracic echocardiographic
follow-up  due  to  progression  of  AR  and  development  of  heart  failure,  the  patient  was
qualified to surgical replacement of the aortic valve. This procedure significantly improved
the patient's quality of life.
Summary: The  key  element  in  the  treatment  of  chronic  asymptomatic  AR  is  the
individualization of the therapy. An essential role is played by appropriate pharmacotherapy,
precise monitoring using transthoracic echocardiography, which is recommended as the first-
line imaging strategy. Delaying in the implementation of surgical  treatment  may result  in
failure of the therapy and the onset of serious complications.
Key words: aortic regurgitation, asymptomatic, aortic valve replacement
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Introduction
Chronic  aortic  valve  regurgitation  (AR,  aortic  regurgitation)  is  a  heart  defect
occurring in about 13% of men and 8.5% of women. Its incidence increases significantly with
age, with the peak falling between the 4th and 6th decades of life  [1, 2]. The  degenerative
changes developing with age, as a result of progressive fibrosis and calcification of the valve
leaflets are the main risk factors of AR and they are observed in about 50% of diagnosed
cases.  Other  factors  that predispose to  the development  of this  defect  include:  a  bicuspid
aortic valve (15%), rheumatic fever (15%), infective endocarditis (10%), aortic inflammation
(5%),  as  well  as  connective  tissue  systemic  diseases  (ankylosing  spondylitis,  rheumatoid
arthritis), severe chronic hypertension, Marfan syndrome, atherosclerosis, and aortic injuries
and radiotherapy [3]. The pathogenesis of this disorder is based on the retrograde blood flow
from the aorta to the left ventricle during closing of the aortic valve. The gradually increasing
diastolic  heart  overload  leads  to  compensatory  changes  of  the  left  ventricle,  including
eccentric hypertrophy of the walls, increased susceptibility and enlargement of its cavity.  
The defect is usually characterized by asymptomatic course lasting several months or
even many years. Patients are then in a chronic, compensated phase of the disease. However,
with the passage of time, hemodynamic disorders intensify with subsequent decompensation.
The consequence of this is an irreversible failure of the left ventricle, as well as an increased
risk of sudden cardiac death [4, 5].     
Aim of the work
The  aim  of  this  work,  based  on  the  presented  clinical  case,  was  to  analyze  the
difficulties  in  determining  the  appropriate  time  of  qualification  for  surgical  treatment  of
patients with long-term asymptomatic AR and to show the consequences that would result
from the delay in making such a decision.
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Case report
A 62-year old man, in 2003 underwent coronarography examination, which revealed
critical stenosis of the right coronary artery (RCA) on the border of the central and proximal
section,  in  the  discharge place  of  the  marginal  branch.  In  addition,  a  stenosis  of  a  distal
section of the trunk of the left main coronary artery (LMCA) was made visible in 50-60%,
and small mural changes of the left anterior descending artery (LAD), diagonal artery (DA),
ramus intermedius artery (RI) and circumflex artery (Cx) were also proved. At the same time,
the radionuclide ventriculography (RVG) scan showed insignificant dilatation of the left heart
ventricle  without  disorder  of  contractility  with  left  ventricular  end-diastolic  diameter
(LVEDD) – 18 mmHg, the aortic  valve insufficiency was not determined back then.  The
patient was qualified for surgical treatment, and in June 2003 he underwent the LIMA-LAD
(left  anterior mammary artery – left  anterior descending) surgery, Ao-OM1  (aorta – first
obtuse marginal) and Ao-RCA (aorta – right coronary artery) surgeries. Echocardiography
check-up performed 2 years later, showed symmetric overgrowth and dilatation of the left
heart ventricle with LVEDD – 6.3 cm and with the IVsd – 1.5 cm  (interventricular septal
thickness  at  diastole).  Additionally,  first  degree  mitral  insufficiency  with  second  degree
tricuspid insufficiency and second degree aortic valve insufficiency were diagnosed. Based on
the  double  computer  tomography  and  during  regular  echocardiographic  examinations
performed in the subsequent years, progressive dilatation of the heart was observed in the area
of left ventricle with left ventricle ejection fraction (LVEF) – 50% as well as disorders in its
contractility in the form of sectional septum hypokinesis, frontal and lateral walls. Chronic
heart  insufficiency  was  diagnosed  in  the  NYHA  I  class.  Also,  an  aneurysm  bulge
(13x10x5mm)  occurred  on  the  frontal  wall  of  the  part  of  ascending  aorta.  In  turn,
insufficiency of the tricuspid aorta valve progressed (III degree).  The ECHO examination
revealed a significant insufficiency of the valve, that is improper shape and movement of the
non-coronary cusp, and to a smaller extent, of the right one, both in the closing and opening
phase of the valve. Moreover, first degree hypertension developed in the patient. During the
physical  examination  at  the  left  edge  of  the  sternum,  a  holodiastolic  murmur  of  the
decrescendo type (so called „seagull’s cry murmur”) was heard, at about 4/6 in the Levine
scale. What is interesting, during the physical examination, despite progression of the aortic
insufficiency,  no  alarming  symptoms,  i.e.  deterioration  of  physical  exertion  tolerance,
shortness of breath, pain in the chest or palpitations, were recorded.  In 2011 on the basis of
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the coronarography and aortography examinations, the closure of the LIMA-LAD graft as
well as the progression of aortic insufficiency (III/IV degree) were diagnosed. Chronic heart
insufficiency evolved into the NYHA II degree, with LVEF – 45%. Nonetheless, due to the
lack  of  significant  clinical  symptoms,  the  surgery  of  the  defect  was  deferred  and it  was
decided to wait for the next 2 years.  In the preventive treatment, beta blockers, aspirin, loop
diuretics  and  ACE inhibitors  were  used.  Due  to  such  pharmacological  treatment,  in  the
following years a progressive drop of diastolic pressure was recorded – down to the value of
45 mmHg – as well as a significant increase in the LVEDD value to 7.2 cm [Fig.1, Fig. 2, Fig.
3., Table 1]. Increase of the dimensions of the left heart ventricle and dilatation of the upper
lobal  veins  were  also  made  visible  in  the  performed  chest  X-ray  [Fig  4].  The
electrocardiogram (ECG) presented the features of the overload of the left heart ventricle. As
a  result  of  the  above-mentioned  changes,  the  patient  was  qualified  for  re-operation.  On
23.08.2013  the  coronary  artery  bypass  graft  (CABG)  Ao-LAD  was  conducted  with
simultaneous implantation of the biological prosthesis of the aortic valve Hancock II no. 25.
After implantation, the valve undertook proper function with PG max  (maximum pressure
gradient) – 32 mmHg, PG mean – 18 mmHg, Vmax – 2.8 m/s, and LVEF increased to 50%.
In the postoperative period, there were several heart rhythm disorders, in the form of atrial
fibrillation.  The  return  to  the  sinus  rhythm  was  obtained  by  means  of  pharmacological
treatment.  The  patient  in  a  general  good  condition  was  discharged  home  with
recommendations  such  as  warfarin,  amiodaron,  furosemide,  bisoprolol,  spironolactone,
ramipryl, acetylsalicylic acid.
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Figure 1.  Transthoracic  echocardiogram.  Parasternal  projection  in  the long axis.  A small
volume of fluid is visible in the pericardial sac. Widening of the aortic bulb. Thickened aortic
valve leaflets.
Figure  2. Transthoracic  echocardiogram.  4-chamber  apical  projection.  Color  Doppler
examination  technique.  Left  ventricular  enlargement  and  return  wave  of  large  aortic
regurgitation are visible.
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Figure  3. Transthoracic  echocardiogram.  Short  sternal  projection.  Reverse  blood  flow is
visible. Qualitative (on a scale from 1 + to 4+) assessment of the range of the return wave of
aortic regurgitation.
Figure 4. X-ray image of the patient's chest. Enlargement of the transverse dimension of the
left ventricle, prominent aortic arch, widening of the high lobe veins and upper mediastinum
(thyroid?) are visible.
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Table 1. Data summary based on echocardiographic control protocols since the first discovery
of AR in 2005. 
Discussion
Chronic  AR in  most  cases  is  characterized  by  a  long-term  asymptomatic  course.
Nevertheless,  despite  the  lack  of  noticeable  clinical  symptoms  of  this  defect,  a  gradual
increase in the volume of the return blood flow and the left ventricular end-diastolic volume
(LVEDV)  is  observed.  The  consequence  of  the  described  hemodynamic  changes  is  the
progressive myocardial remodeling in the form of myocyte hypertrophy and reorganization of
the extracellular matrix [6]. According to scientific reports, such altered heart can weigh up to
1000 g at autopsy [2]. Initially activated compensatory mechanisms have become exhausted
over  time,  leading  to  an  irreversible  left  ventricular  dysfunction.  As  a  result,  clinical
symptoms  appear  in  25% of  cases  in  the  period  of  one  year  after  decompression  of  left
ventricular function [3]. The most common first manifestation of chronic AR is exertional
dyspnoea,  fatigue,  and a  decrease in exercise tolerance.  During the physical  examination,
attention  is  drawn to  the  significant  amplitude  of  blood  pressure  with  increased  systolic
pressure  and  often  indeterminate  diastolic  pressure,  with  coexisting  Corrigan’s  pulse.
Therefore, auscultation of the heart is particularly important in the initial diagnosis of valvular
heart diseases. It is not uncommon that confirmation of the diagnosis of severe AR is a loud,
holodiastolic  decrescendo  murmur,  so-called  seagull’s  cry  murmur,  also  known  as
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Gallavardin’s phenomenon, best heard at the left side of the sternum. It was first described by
French physician Louis Gallavardin and Ravoult in 1925, while studying angina pectoris. This
murmur, imitating the cooing sound of a seagull, is usually characterized by a musical timbre
and a high frequency, appearing when the regurgitant flow presents high velocities [7, 8]. The
above  case  is  therefore  an  accurate  reflection  of  the  characteristic  course  of  this  defect,
because the patient did not report any complaints neither at rest or during physical exercises
during the 10 years of the disease. 
In  assessing  the  severity  of  AR,  monitoring  of  the  follow-up,  and  choosing  the
therapeutic methods, the crucial factors are: semi-quantitative echocardiographic parameters,
such as end-systolic left ventricular diameter (LVESD), LVEDD, and LVEF assessed in the
transthoracic echocardiographic examination (TTE). Besides, colour Doppler is recommended
as  a  noninvasive,  highly sensitive  and specific  technique  for  detecting  AR and providing
visualization of the regurgitant jet. At the same time, continuous and pulsed wave Doppler as
a quantitative method,  provides additional  haemodynamic information.  Nowadays,  beyond
commonly  used  two-dimensional  (2D)  imaging  echo,  three-dimensional  (3D)
echocardiography,  tissue  Doppler  and  strain  rate  imaging  have  increasing  importance  in
obtaining accurate measurements and assessment of valve morphology, especially in patients
with borderline left ventricular ejection fraction. While it is recommended that patients with
mild to moderate AR can be reviewed once a year, and echocardiography performed every 2
years, all asymptomatic patients with severe AR and normal left ventricular function should
be seen for a follow-up at least every year or even at 3-6 months intervals in case of newly
diagnosed patients. This includes also patients with rapid progression of AR, or who come
close to thresholds for surgery. ECG, which may be normal in mild AR and may show LV
hypertrophy in moderate to severe AR, plays a significant role among other diagnostic tools.
Besides, chest X-ray also has important meaning, as it may reveal LV enlargement, as well as
aneurismal dilatation of the ascending aorta, usually occurring in patients with AR coexisting
with primary disease of the aortic wall. The above-mentioned diagnostic methods have proven
to  be  extremely  useful  in  assessing  the  described  patient’s  case,  and  highlighted  typical
changes  for  AR.  RVG,  which  was  performed  on  our  patient,  is  rarely  used  to  serial
assessment  of  LVEF  at  rest  and  during  exercise.  Either  the  cardiac  magnetic  resonance
(CMRI),  or  the  subsequent  invasive  diagnostic  methods  such as  aortic  root  angiography,
should be considered only when the diagnosis cannot be determined by noninvasive imaging
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and when patients have suspected or known coronary artery disease (CAD), especially those
with previous CABG [4, 9-11].
Pharmacological  treatment and surgical  intervention – an ideal  moment for  optimal
surgical decision
The standard procedure in heart valve disease in everyday clinical practice of not only
cardiologists, but also cardiac surgeons, is based on the guidelines issued by the American
College of Cardiology, American Heart Association, and  ESC/EACTS as well. Nowadays,
pharmacological treatment and surgical intervention are mentioned among approved methods
for the treatment of AR.
Vasodilatative drugs are taken into account in the pharmacological management. They
mainly reduce LVEDV, strain of blood vessel wall  and afterload,  while  at  the same time
improve the function of the left ventricle and reduce its mass. Nevertheless, their effectiveness
has  not  been  clinically  confirmed  so  far.  Previous  observations  have  displayed  that  the
therapy with angiotensin-converting-enzyme inhibitors (ACEI), angiotensin receptor blockers
(ARB) or dihydropyridine calcium channel blockers (CCBs) is justified only in the case of
coexistence of AR and hypertension, because of their hypotensive effect, like in the discussed
patient [6, 12-13]. 
Initially  suggested  advantageous  influence  of  vasodilators  in  prolonging  the
asymptomatic period and postponing the surgical intervention in the sick with normal blood
pressure  has  not  been  shown unambiguously.  Furthermore,  it  is  worth  to  emphasise  that
during beta-adrenolytic treatment in high-grade AR, special caution should be exercised due
to their influence on prolonging diastolic time with simultaneous increasing the volume of
regurgitation [14]. It is also recommended to treat patients with hydralazine [12]. Patients
with  normal  LVEDD  do  not  need  pharmacological  management,  while  the  ones  with
increased LVEDD are recommended to take nifedypine or  ACEI, as long as there are no
contraindications to prescribe them. In case of the described patient,  the use of mentioned
drugs (ramipryl, bisoprolol), resulted in a good therapeutic effect. According to most recent
guidelines issued by ESC/EACTS 2017 it is also suggested to continue the treatment with
ACEI,  ARB  or  beta-adrenolytics  in  patients  who  have  had  heart  failure  symptoms  or
hypertension in spite of surgery replacement of the aortic valve.
The appropriate moment to qualify the patient with asymptomatic AR, especially high-
grade,  to  reparative  surgery,  is  extraordinarily  essential  from  the  viewpoints  of  distant
consequences,  the  prognosis,  as  well  as  the  quality  of  life.  It  is  thought  that  not  until
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symptoms develop, or significant extension and dysfunction of the left ventricle occur, the
decision to surgical replacement of the valve generally may be postponed without higher risk
in this group of patients. According to the newest guidelines issued by ESC/EACTS 2017, as
well as defined criteria during qualification of discussed patient with high-grade AR to the
operation (2013), absolute recommendations are: impairment of LV function (LVEF)  ≤50%,
LV enlargement  with LVEDD >70mm or LVESD >50 mm [9-10]. In the described case,
symptomless 62-year-old patient with LVEF = 50%, LVEDD = 72 mm and previous CABG
surgery is  in  the I  class of the recommendation,  in  which evidence  for effectiveness  and
clinical utility of a surgical intervention is unambiguous, and there are strong circumstances
as to its validity.  Recommendations for surgical treatment in analysed case in the light of
current best-evidence guidelines were summarized in table 2 [Table 2].
Clinical observations show that the outcomes of early surgical management on patients
with  at  most  moderate  left  ventricle  systolic  dysfunction  in  the  NYHA I  or  II  class  are
generally good, and the perioperative mortality rate does not exceed 1-3%, whereas the distant
survival is similar to the general population [15]. According to the available literature data, in
patients with asymptomatic AR with initially preserved left ventricle systolic function (LVEF
≥50%), its  symptomless dysfunction develops in <1.3% patients  annually,  and the rate  of
sudden, unexpected death in this group is lower than 0.2% annually [15].
Age, as an unmodifiable risk factor, worsens the prognosis of the surgery. Moreover,
the individuals who underwent CABG, aortic or other heart valve surgery are in the special
risk factor group. Multidisciplinary team decision-making to perform the operation should
also take into account aetiology of AR, the life expectancy and operative risk in every patient.
Table 2. Recommendations for the surgical intervention in patients with asymptomatic AR.
LVEF/EF – ejection fraction, LVEDD – left ventricle end-diastolic diameter,  AOd – aortic
root diameter
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Documented cases and observational studies in the literature
Scientific reports confirm that evaluation of hemodynamic changes in the course of
asymptomatic AR, as well as that clinical status of patients are integral parts of the treatment.
In the literature, we can find numerous examples confirming the importance of assessing not
only the size and systolic function of the left ventricle, but also quantitative parameters (left
ventricular  end-diastolic  pressure  –  LVEDP,  aortic  regurgitant  volume  –  RV,  aortic
regurgitant fraction – RF) and the effect of the extra-valvular factor – anatomy of ascending
aortic root (AO). In the study of 126 patients (33 women and 93 men, mean age 35 ± 11
years) with asymptomatic AR undergoing long-term follow-up (mean time 7 ± 3 years), it was
found that clinical and echocardiographic status of 107 patients was stable, which constituted
84.92% of examined ones [16]. It was observed that only AOd has increased, but merely in
patients  with  increased  LVEDD and  both  tricuspid  and  bicuspid  valve.  It  has  also  been
proven, that all investigated parameters: age, LVEDD, LVEF, LVEDP, RF, RV and aortic
root diameter (AOd), have significant prognostic values in the evaluation of AR progression.
Aortic valve replacement (AVR) procedure was performed in 19 patients, but the frequency
of the indication to AVR due to hemodynamic progression (n=7) and gradual significant AOd
(n=7) was similar.  An important  conclusion from the study is the fact that an increase in
LVEDP by 1 mmHg above the norm enhances the risk of AVR by as much as 83%. It has
also been demonstrated that the probability of a 10-year survival by patients with chronic AR
without the necessity for surgery AVR is 85%. In the analyzed case of our patient, AVR was
also performed after 10 years of observation. 
On  the  other  hand,  the  case  of  a  23-year-old  patient  with  asymptomatic  AR and
hypertension demonstrates the importance of systematic monitoring by means of subsequent
echocardiographic  examinations  and determining the adequate  time to qualify  for surgery
before irreversible  changes,  that prevent recovery of normal  left  ventricular  function after
surgical correction of the defect, develop [15]. It should be remembered that although the
irreversible deterioration of left  ventricular  function is usually accompanied by congestive
heart failure symptoms, they may sometimes occur imperceptibly, without clinical symptoms.
In the aforementioned case, it was decided to carry out the surgical treatment of the defect due
to  enlargement  of  the  LVEDD  from 63  to  73  mm during  2  years  of  observation,  with
identified echocardiographic features of elevated diastolic pressure in the left ventricle as well
as no improvement after pharmacological treatment.
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Summary
Chronic AR is often characterized by many years of asymptomatic course. While it is
not  difficult  to  identify  hemodynamically  significant  AR and to  assess  its  stage,  it  is  an
enormous problem for both cardiologists and cardiac surgeons to determine the indications for
surgical  treatment  at  the  most  adequate  time,  especially  in  an  asymptomatic  patient.
Moreover, performing the surgery at the appropriate time prevents any irreversible damage to
the left ventricular muscle that could occur if surgery was delayed. Then, the correction of the
defect would not lead to a reduction in the diameter of the left ventricle and improvement of
its  function.  Parameters  such  as:  age,  LVEDD,  LVEF,  LVEDP,  RF,  RV,  AOd  have
significant  value  in  predicting  progression  of  the  defect  and  qualification  for  surgical
treatment.  Therefore,  systematic  and  regular  monitoring  by  means  of  subsequent
echocardiographic assessment of left ventricular dimensions and its functional parameters, as
well  as  close  evaluation  of  the  patient's  clinical  condition,  is  of  fundamental  importance.
Pharmacological treatment with beta-blockers, ACE inhibitors and dihydropyridine calcium
antagonists should be considered in regards to patients with normal left ventricular function.
There is no universal single treatment protocol for patients with asymptomatic AR. Although
there  are  general  guidelines  for  the  management  of  AR,  in  each  case  therapy  should  be
individualized and adapted to the patient's clinical condition as well as comorbidities.
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